WuXi Biologics Opens Biologics Mfg Facility
WuXi Biologics, part of WuXi AppTec, a contract service provider, has opened its cGMP biologics manufacturing facility in Wuxi, China for full operations.
In April 2015, WuXi Biologics announced a $150-million investment to build a biologics manufacturing facility in Wuxi, China. In September 2016, the first phase of construction was completed with two 1,000-liter disposable bioreactors for perfusion processes. Fifteen months later, a cGMP campaign was started in the second phase of the cGMP facility, which is now equipped with 14 additional 2,000-liter disposable bioreactors for fed-batch cell culture.
WuXi Biologics says the new facility quintuples the existing manufacturing capability of WuXi Biologics. This facility will support the biologics commercial manufacturing pipeline. In addition, the company says that the newly added capacity will offer service for Chinese companies as biologics contract manufacturing for Chinese companies is recently being piloted by the China Food and Drug Administration.
The new 500,000-square-foot manufacturing facility with 30,000-liter bioreactor capacity will add to WuXi Biologics’ existing biologics manufacturing capabilities. In 2012, WuXi completed its first biologics drug-substance and drug-product manufacturing facilities in Wuxi, China.
Source: WuXi Biologics